Molecule Details
InChIKeyDGBIGWXXNGSACT-UHFFFAOYSA-N
Compound NameClonazepam
Canonical SMILESO=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1
Clinical Status Data-mined Candidate
Targets (Human+Pathogen)16
Pfam Stratification Homologous
Avg pChEMBL9.04
SourceBindingDB;ChEMBL
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB01068
Drug NameClonazepam
CAS Number1622-61-3
Groups approved illicit investigational
ATC Codes N03AE01
DescriptionA benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F37...

Categories: Anticonvulsants Benzazepines Benzodiazepines and benzodiazepine derivatives Benzodiazepinones Central Nervous System Agents Central Nervous System Depressants Cytochrome P-450 CYP2E1 Inhibitors Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Drugs that are Mainly Renally Excreted GABA Agents GABA Modulators Heterocyclic Compounds, Fused-Ring Muscle Relaxants Muscle Relaxants, Centrally Acting Agents Nervous System
Cross-references: BindingDB: 50019213 ChEBI: 3756 CHEMBL452 ChemSpider: 2700 Drugs Product Database (DPD): 2192 D00280 PharmGKB: PA449050 PubChem:2802 PubChem:46507677 RxCUI: 2598 Therapeutic Targets Database: DAP000259 Wikipedia: Clonazepam ZINC: ZINC000003813003
Target Activities (16)
Target Gene Organism Category Pfam pChEMBL Type Source
O00591 GABRP Homo sapiens Human PF02931 PF02932 9.1 Ki ChEMBL
O14764 GABRD Homo sapiens Human PF02931 PF02932 9.1 Ki ChEMBL
P18505 GABRB1 Homo sapiens Human PF02931 PF02932 9.1 Ki ChEMBL
P18507 GABRG2 Homo sapiens Human PF02931 PF02932 9.1 Ki ChEMBL
P28472 GABRB3 Homo sapiens Human PF02931 PF02932 9.1 Ki ChEMBL
P31644 GABRA5 Homo sapiens Human PF02931 PF02932 9.1 Ki ChEMBL
P47870 GABRB2 Homo sapiens Human PF02931 PF02932 9.1 Ki ChEMBL
P48169 GABRA4 Homo sapiens Human PF02931 PF02932 9.1 Ki ChEMBL
P78334 GABRE Homo sapiens Human PF02931 PF02932 9.1 Ki ChEMBL
Q16445 GABRA6 Homo sapiens Human PF02931 PF02932 9.1 Ki ChEMBL
Q8N1C3 GABRG1 Homo sapiens Human PF02931 PF02932 9.1 Ki ChEMBL
Q99928 GABRG3 Homo sapiens Human PF02931 PF02932 9.1 Ki ChEMBL
Q9UN88 GABRQ Homo sapiens Human PF02931 PF02932 9.1 Ki ChEMBL
P14867 GABRA1 Homo sapiens Human PF02931 PF02932 9.0 Ki ChEMBL;BindingDB
P47869 GABRA2 Homo sapiens Human PF02931 PF02932 8.9 Ki ChEMBL;BindingDB
P34903 GABRA3 Homo sapiens Human PF02931 PF02932 8.9 Ki ChEMBL;BindingDB
DrugBank Target Actions (6)
Target Gene Target Name Action Type
P02768 ALB Albumin binder carriers
P05181 CYP2E1 Cytochrome P450 2E1 inhibitor enzymes
P08684 CYP3A4 Cytochrome P450 3A4 substrate enzymes
P11245 P11245 Arylamine N-acetyltransferase 2 substrate enzymes
O75469 NR1I2 Nuclear receptor subfamily 1 group I member 2 partial agonist targets
P14867 GABRA1 GABA(A) Receptor Benzodiazepine Binding Site positive allosteric modulator targets